0.09Open0.75Pre Close2 Volume237 Open Interest42.00Strike Price22.00Turnover88.83%IV16.48%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.13Extrinsic Value100Contract SizeAmericanOptions Type0.1217Delta0.0461Gamma144.68Leverage Ratio-0.0641Theta0.0008Rho17.60Eff Leverage0.0100Vega
Exelixis Stock Discussion
Breakthrough: CABOMETYX Becomes First FDA-Approved Treatment for All Advanced NET Cancers
Exelixis Reveals Breakthrough Cancer Pipeline: 4 Novel Drugs Show Promise in Early Data
2.Based on the fourth-quarter and fiscal year 2024 financial report, Exelixis, Inc. demonstrated excellent performance. For the fourth quarter, the company reported net income of $139.9 millio...
Revolutionary Kidney Cancer Treatment Doubles Patient Survival: Final 5-Year Trial Results Revealed
No comment yet